Munich - Delayed Quote EUR

Roche Holding AG (RHO5.MU)

278.70

+1.00

+(0.36%)

At close: May 30 at 8:06:37 AM GMT+2

Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years

Roche Holdings AG (OTC:RHHBY) on Friday announced new 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low disease activity levels for up to two years. The latest results for this investigational Bruton’s tyrosine kinase (BTK) inhibitor from the Phase II FENopta open-label extension (OLE) study were presented at the Consortium of Multiple Sclerosis Centers (CMSC) Annual Meeting. Ninety-nine patients entered

Benzinga 8 hours ago

ROG.SW
Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

Patients on fenebrutinib had low relapse rates with data showing no active brain lesions or disability progression after nearly two years of treatmentPhase III studies for fenebrutinib in relapsing and primary progressive multiple sclerosis are expected to start reading out at year end Basel, 30 May 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today new, 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression a

GlobeNewswire 21 hours ago

RHHBF

RHHBY

RHHVF
Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis

SOUTH SAN FRANCISCO, Calif., May 30, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today new, 96-week data for fenebrutinib demonstrating that patients with relapsing multiple sclerosis (RMS) maintained no disability progression and low levels of disease activity for up to two years. The latest results for this investigational Bruton’s tyrosine kinase (BTK) inhibitor from the Phase II FENopta open-label extension (OLE) study were presented at the Consortium

Business Wire 21 hours ago

RHHBF

RHHBY

RHHVF
This new antibiotic may finally put a stop to some of the world’s most drug-resistant pathogens

Swiss pharma giant Roche says its new antibiotic zosurabalpin will progress to phase 3 testing. It’s the first drug in its class since 1968.

FastCompany yesterday

ROG.SW
The Zacks Analyst Blog Highlights Alphabet, Bank of America, Roche, Village Super Market and Aware

Zacks spotlights Alphabet, Bank of America, Roche, Village Super Market and Aware in fresh analyst reports highlighting key drivers and risks.

Zacks yesterday

GOOG

ROG.SW

VLGEA
Top Analyst Reports for Alphabet, Bank of America & Roche

Alphabet gains on AI-driven cloud, while YouTube and Google One push subscriptions past 270M despite litigation and cloud competition concerns.

Zacks 2 days ago

ROG.SW

GOOG
Mapping out opportunities to reduce emissions in clinical trials

At CTO West Coast an expert from Genentech outlined the company’s net zero goals, efforts, challenges and initiatives tailored to clinical trials.

Clinical Trials Arena 2 days ago

ROG.SW
Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

PRTA shares drop 22% after ending birtamimab development as a phase III study fails to meet primary or secondary endpoints in AL amyloidosis.

Zacks 3 days ago

PRTA

ROG.SW

NVO
Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer

RHHBY's Itovebi combo wins CHMP backing for PIK3CA-mutated breast cancer, showing strong survival benefits in phase III INAVO120 study.

Zacks 4 days ago

ROG.SW

PFE

AZN
Roche and Broad Clinical Labs to partner on advancing SBX technology

The initial focus of the partnership will be on trio-based whole genome sequencing for critically ill newborns.

Medical Device Network 4 days ago

ROG.SW
Tandem Diabetes and Roche Reach a Patent Settlement

Tandem Diabetes Care, Inc. (NASDAQ:TNDM) has agreed to pay Roche $36 million to resolve a patent infringement lawsuit over Tandem’s t:slim X2 insulin pump. The deal settles all pending and prospective litigation about two European patents that Roche filed in December 2023, EP 2 196 231 B1 and EP 1 970 677 B1. Over the […]

Insider Monkey 5 days ago

TNDM

ROG.SW
Tandem Diabetes, Roche enter patent settlement agreement

In a regulatory filing, Tandem Diabetes Care (TNDM) disclosed that Tandem and Roche (RHHBY) entered into a Settlement, Mutual Release and Cross-License Agreement to resolve all actual or potential patent disputes as of the effective date relating to the company’s t:slim X2 pump and EP Patent No. 2 196 231 B1 and EP Patent No. 1 970 677 B1, including the pending patent infringement actions, revocation actions, counterclaims for revocation and actions for declaration of non-infringement of patents

TipRanks 6 days ago

TNDM

RHHBF

RHHBY
Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication

FDA approves RHHBY's Susvimo for diabetic retinopathy, its third indication, offering 9-month relief with one treatment.

Zacks 7 days ago

ROG.SW

REGN

PFE
Genentech to onshore US manufacturing amid rising drug pricing tensions

As the administration pushes for a return to US manufacturing, outsourcing agreements with domestic manufacturers are increasing.

Pharmaceutical Technology 7 days ago

ROG.SW
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%

The new OS results came from the Phase III INAVO120 study evaluating an Itovebi triple combination therapy.

Clinical Trials Arena 7 days ago

ROG.SW
CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

Positive recommendation based on phase III INAVO120 data showing ItovebiTM (inavolisib) in combination with palbociclib and fulvestrant more than doubled progression-free survival in the first-line setting1The Itovebi-based regimen also demonstrated a statistically significant and clinically meaningful benefit in overall survival (OS) in the final OS analysisFinal OS data will be presented in an oral session at the 2025 American Society of Clinical Oncology Annual Meeting Basel, 23 May 2025 - Ro

GlobeNewswire 7 days ago

RHHBF

RHHBY

RHHVF
Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo

An EMA committee has issued a positive opinion for a label extension that would allow six-month injection intervals for Eylea 8mg.

Pharmaceutical Technology 7 days ago

ROG.SW

BAYN.DE
Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology

The strategic collaboration with Broad Clinical Labs will explore and develop applications using Roche’s SBX sequencing technology1, with an initial focus on critically ill newborns and their parents.Whole genome sequencing can help diagnose babies with suspected genetic disorders, such as cystic fibrosis and sickle cell disease.This project will explore how this technology could become part of routine clinical practice for newborns, as well as its use in other research applications. Basel, 23 M

GlobeNewswire 7 days ago

RHHBF

RHHBY

RHHVF
$New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients$

New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients

Updated data from the pivotal phase III STARGLO study continue to demonstrate a clinically meaningful improvement in overall survival with a 40% survival benefit for people with R/R DLBCL who are not candidates for transplant189% of patients whose cancer had fully responded at the end of treatment with Columvi in combination with chemotherapy were still alive and 82% showed no signs of cancer one year post-treatment1Timely initiation of effective therapy at relapse or after initial therapy failu

GlobeNewswire 7 days ago

RHHBF

RHHBY

RHHVF
$New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients$

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients

SOUTH SAN FRANCISCO, Calif., May 23, 2025--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today two-year follow-up data from the Phase III STARGLO study. After a median follow-up of 24.7 months, data showed a 40% improvement in overall survival (OS) for patients treated with Columvi® (glofitamab-gxbm) in combination with gemcitabine and oxaliplatin (GemOx) and median OS was not reached, compared to 13.5 months for Rituxan® (rituximab) plus GemOx (R-GemOx). These u

Business Wire 7 days ago

RHHBF

RHHBY

RHHVF

Performance Overview

Return	RHO5.MU	MSCI WORLD (^990100-USD-STRD)
YTD	+17.82%	+3.89%
1-Year	+17.82%	+12.64%
3-Year	+27.52%	--

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Roche Holding AG (RHO5.MU)

Roche's Multiple Sclerosis Drug Shows Low Disease Activity Over Two Years

Roche’s fenebrutinib maintains near-complete suppression of disease activity and disability progression for up to two years in people with relapsing multiple sclerosis

Genentech’s Fenebrutinib Maintains Near-Complete Suppression of Disease Activity and Disability Progression for up to Two Years in People With Relapsing Multiple Sclerosis

This new antibiotic may finally put a stop to some of the world’s most drug-resistant pathogens

The Zacks Analyst Blog Highlights Alphabet, Bank of America, Roche, Village Super Market and Aware

Top Analyst Reports for Alphabet, Bank of America & Roche

Mapping out opportunities to reduce emissions in clinical trials

Prothena's Late-Stage Study for AL Amyloidosis Fails, Stock Down

Roche Gets CHMP Nod for Itovebi Combo in the EU for Breast Cancer

Roche and Broad Clinical Labs to partner on advancing SBX technology

Tandem Diabetes and Roche Reach a Patent Settlement

Tandem Diabetes, Roche enter patent settlement agreement

Roche Gets FDA Nod for Label Expansion of Susvimo for Third Indication

Genentech to onshore US manufacturing amid rising drug pricing tensions

ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%

CHMP recommends EU approval of Roche’s Itovebi for PIK3CA-mutated, ER-positive, HER2-negative, advanced breast cancer

Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo

Roche announces new collaboration with Broad Clinical Labs to accelerate adoption of cutting-edge SBX sequencing technology

New two-year follow-up of Roche’s Columvi extends overall survival in relapsed or refractory diffuse large B-cell lymphoma patients

New Two-year Follow-up of Genentech’s Columvi Extends Overall Survival in Relapsed or Refractory Diffuse Large B-cell Lymphoma Patients

Performance Overview